Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series
Abstract Objectives To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody. Methods Nine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE...
        Saved in:
      
    
          | Published in | Rheumatology (Oxford, England) Vol. 61; no. 6; pp. 2625 - 2630 | 
|---|---|
| Main Authors | , , , , , , , , , , , , , | 
| Format | Journal Article | 
| Language | English | 
| Published | 
        England
          Oxford University Press
    
        30.05.2022
     | 
| Subjects | |
| Online Access | Get full text | 
| ISSN | 1462-0324 1462-0332 1462-0332  | 
| DOI | 10.1093/rheumatology/keab629 | 
Cover
| Abstract | Abstract
Objectives
To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody.
Methods
Nine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE therapy at Ruijin Hospital from October 2017 to December 2020. The clinical manifestations, laboratory tests, chest CT and lower extremity MRI images before and after PE therapy were compared. The treatment response was evaluated by the 2016 ACR/EULAR myositis response criteria.
Results
A total of 88.9% (8/9) of subjects had achieved improvement by 3 weeks after PE therapy, with 55.6% (5/9) minimal improvement and 33.3% (3/9) moderate improvement. There were statistically significant improvements between baseline and after PE therapy at 3 weeks on the core set measures: physician global activity, patient global activity, HAQ, manual muscle testing (MMT), extramuscular disease activity, and muscle enzymes activity including creatine kinase (CK), lactate dehydrogenase (LDH), aspartate transaminase (AST), except for alanine transaminase (ALT). Moreover, the chest CT showed regression of ground glass opacities and irregular linear opacities after PE therapy in four patients with interstitial lung disease. The MRI images of lower extremity in four patients showed reduction of muscle oedema after the therapy.
Conclusion
PE therapy is effective for refractory IIM patients with positive anti-SRP antibody. It should be considered as an alternative treatment for those patients who are resistant to the combined therapy of glucocorticoids and immunosuppressive agents. | 
    
|---|---|
| AbstractList | To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody.OBJECTIVESTo explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody.Nine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE therapy at Ruijin Hospital from October 2017 to December 2020. The clinical manifestations, laboratory tests, chest CT and lower extremity MRI images before and after PE therapy were compared. The treatment response was evaluated by the 2016 ACR/EULAR myositis response criteria.METHODSNine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE therapy at Ruijin Hospital from October 2017 to December 2020. The clinical manifestations, laboratory tests, chest CT and lower extremity MRI images before and after PE therapy were compared. The treatment response was evaluated by the 2016 ACR/EULAR myositis response criteria.A total of 88.9% (8/9) of subjects had achieved improvement by 3 weeks after PE therapy, with 55.6% (5/9) minimal improvement and 33.3% (3/9) moderate improvement. There were statistically significant improvements between baseline and after PE therapy at 3 weeks on the core set measures: physician global activity, patient global activity, HAQ, manual muscle testing (MMT), extramuscular disease activity, and muscle enzymes activity including creatine kinase (CK), lactate dehydrogenase (LDH), aspartate transaminase (AST), except for alanine transaminase (ALT). Moreover, the chest CT showed regression of ground glass opacities and irregular linear opacities after PE therapy in four patients with interstitial lung disease. The MRI images of lower extremity in four patients showed reduction of muscle oedema after the therapy.RESULTSA total of 88.9% (8/9) of subjects had achieved improvement by 3 weeks after PE therapy, with 55.6% (5/9) minimal improvement and 33.3% (3/9) moderate improvement. There were statistically significant improvements between baseline and after PE therapy at 3 weeks on the core set measures: physician global activity, patient global activity, HAQ, manual muscle testing (MMT), extramuscular disease activity, and muscle enzymes activity including creatine kinase (CK), lactate dehydrogenase (LDH), aspartate transaminase (AST), except for alanine transaminase (ALT). Moreover, the chest CT showed regression of ground glass opacities and irregular linear opacities after PE therapy in four patients with interstitial lung disease. The MRI images of lower extremity in four patients showed reduction of muscle oedema after the therapy.PE therapy is effective for refractory IIM patients with positive anti-SRP antibody. It should be considered as an alternative treatment for those patients who are resistant to the combined therapy of glucocorticoids and immunosuppressive agents.CONCLUSIONPE therapy is effective for refractory IIM patients with positive anti-SRP antibody. It should be considered as an alternative treatment for those patients who are resistant to the combined therapy of glucocorticoids and immunosuppressive agents. Abstract Objectives To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody. Methods Nine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE therapy at Ruijin Hospital from October 2017 to December 2020. The clinical manifestations, laboratory tests, chest CT and lower extremity MRI images before and after PE therapy were compared. The treatment response was evaluated by the 2016 ACR/EULAR myositis response criteria. Results A total of 88.9% (8/9) of subjects had achieved improvement by 3 weeks after PE therapy, with 55.6% (5/9) minimal improvement and 33.3% (3/9) moderate improvement. There were statistically significant improvements between baseline and after PE therapy at 3 weeks on the core set measures: physician global activity, patient global activity, HAQ, manual muscle testing (MMT), extramuscular disease activity, and muscle enzymes activity including creatine kinase (CK), lactate dehydrogenase (LDH), aspartate transaminase (AST), except for alanine transaminase (ALT). Moreover, the chest CT showed regression of ground glass opacities and irregular linear opacities after PE therapy in four patients with interstitial lung disease. The MRI images of lower extremity in four patients showed reduction of muscle oedema after the therapy. Conclusion PE therapy is effective for refractory IIM patients with positive anti-SRP antibody. It should be considered as an alternative treatment for those patients who are resistant to the combined therapy of glucocorticoids and immunosuppressive agents. To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition particle (SRP) antibody. Nine refractory IIM patients with positive anti-SRP antibody were enrolled, who received PE therapy at Ruijin Hospital from October 2017 to December 2020. The clinical manifestations, laboratory tests, chest CT and lower extremity MRI images before and after PE therapy were compared. The treatment response was evaluated by the 2016 ACR/EULAR myositis response criteria. A total of 88.9% (8/9) of subjects had achieved improvement by 3 weeks after PE therapy, with 55.6% (5/9) minimal improvement and 33.3% (3/9) moderate improvement. There were statistically significant improvements between baseline and after PE therapy at 3 weeks on the core set measures: physician global activity, patient global activity, HAQ, manual muscle testing (MMT), extramuscular disease activity, and muscle enzymes activity including creatine kinase (CK), lactate dehydrogenase (LDH), aspartate transaminase (AST), except for alanine transaminase (ALT). Moreover, the chest CT showed regression of ground glass opacities and irregular linear opacities after PE therapy in four patients with interstitial lung disease. The MRI images of lower extremity in four patients showed reduction of muscle oedema after the therapy. PE therapy is effective for refractory IIM patients with positive anti-SRP antibody. It should be considered as an alternative treatment for those patients who are resistant to the combined therapy of glucocorticoids and immunosuppressive agents.  | 
    
| Author | Sun, Yue Chi, Huihui Liu, Honglei Cheng, Xiaobing Zhang, Hao Ye, Junna Su, Yutong Zhou, Zhuochao Liu, Tingting Jia, Jinchao Wang, Mengyan Yang, Chengde Hu, Qiongyi Teng, Jialin  | 
    
| Author_xml | – sequence: 1 givenname: Hao surname: Zhang fullname: Zhang, Hao – sequence: 2 givenname: Yue surname: Sun fullname: Sun, Yue – sequence: 3 givenname: Honglei surname: Liu fullname: Liu, Honglei – sequence: 4 givenname: Xiaobing surname: Cheng fullname: Cheng, Xiaobing – sequence: 5 givenname: Junna surname: Ye fullname: Ye, Junna – sequence: 6 givenname: Qiongyi orcidid: 0000-0002-4825-5227 surname: Hu fullname: Hu, Qiongyi – sequence: 7 givenname: Jinchao surname: Jia fullname: Jia, Jinchao – sequence: 8 givenname: Mengyan surname: Wang fullname: Wang, Mengyan – sequence: 9 givenname: Tingting surname: Liu fullname: Liu, Tingting – sequence: 10 givenname: Zhuochao surname: Zhou fullname: Zhou, Zhuochao – sequence: 11 givenname: Chengde surname: Yang fullname: Yang, Chengde – sequence: 12 givenname: Huihui orcidid: 0000-0001-9587-1180 surname: Chi fullname: Chi, Huihui – sequence: 13 givenname: Jialin surname: Teng fullname: Teng, Jialin – sequence: 14 givenname: Yutong orcidid: 0000-0002-0358-8933 surname: Su fullname: Su, Yutong email: suyt2015@163.com  | 
    
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34508561$$D View this record in MEDLINE/PubMed | 
    
| BookMark | eNqNkU1v1DAQhi1URD_gH6DKx17StZ3v3qoKWqRK5QBna-KMNwbHDrajkn9PtrtFVS9wskd-nhl53lNy5LxDQj5ydslZm2_CgPMIyVu_XTY_EbpKtG_ICS8qkbE8F0d_76I4Jqcx_mCMlTxv3pHjvChZU1b8hCxfLcQRKP5WA7gt0jRggGmhxtGAOoBKPuwqbWHcjVuLcfETpGGhjyYNFFwyWTRbB3Y1lN86k4x3dIKQjLL4BHS-X64oUAURacRgML4nbzXYiB8O5xn5_vnTt5u77P7h9svN9X2m8qJOme7qnrdNhYwjiEq1rBY9X9-KWkPZ6hr7nmvgZdn1wHmrG4VQsVojtEroKj8jF_u-U_C_ZoxJjiYqtBYc-jlKUda8FUWT1yt6fkDnbsReTsGMEBb5vK4VuNoDKvgY1_1IZRLsvpsCGCs5k7ts5Mts5CGbVS5eyc_9_6Ft9pqfp_8z_gDcSK6z | 
    
| CitedBy_id | crossref_primary_10_1007_s10067_022_06437_z crossref_primary_10_1016_j_biopha_2022_113936 crossref_primary_10_1016_j_jaut_2024_103286 crossref_primary_10_1002_jca_21968 crossref_primary_10_1007_s11910_024_01337_y crossref_primary_10_1002_cti2_1525 crossref_primary_10_3390_jpm14050461  | 
    
| Cites_doi | 10.1002/mus.20693 10.1001/archneur.1981.00510090038003 10.1002/art.20349 10.1093/rheumatology/kez357 10.3389/fmed.2019.00239 10.1097/00001648-199001000-00010 10.1073/pnas.83.24.9507 10.1016/j.transci.2015.07.005 10.1186/s13023-015-0277-y 10.1136/annrheumdis-2018-213518 10.1093/rheumatology/keaa123 10.1001/jamaneurol.2015.1207 10.1136/annrheumdis-2016-210198 10.1056/NEJM197502132920706 10.1136/annrheumdis-2017-211400 10.1056/NEJM199205213262102 10.1093/rheumatology/keu436 10.1136/jnnp-2016-313166  | 
    
| ContentType | Journal Article | 
    
| Copyright | The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.  | 
    
| Copyright_xml | – notice: The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com 2021 – notice: The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.  | 
    
| DBID | AAYXX CITATION NPM 7X8  | 
    
| DOI | 10.1093/rheumatology/keab629 | 
    
| DatabaseName | CrossRef PubMed MEDLINE - Academic  | 
    
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic  | 
    
| DatabaseTitleList | MEDLINE - Academic PubMed  | 
    
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database  | 
    
| DeliveryMethod | fulltext_linktorsrc | 
    
| Discipline | Medicine | 
    
| EISSN | 1462-0332 | 
    
| EndPage | 2630 | 
    
| ExternalDocumentID | 34508561 10_1093_rheumatology_keab629 10.1093/rheumatology/keab629  | 
    
| Genre | Journal Article | 
    
| GrantInformation_xml | – fundername: National Natural Science Foundation of China grantid: 81801600 – fundername: Shanghai Sailing Program grantid: 18YF1414500  | 
    
| GroupedDBID | --- -E4 .2P .GJ .I3 .XZ .ZR 08P 0R~ 18M 1TH 29P 2WC 354 3O- 4.4 48X 53G 5RE 5VS 5WA 5WD 70D AABZA AACZT AAGKA AAJKP AAJQQ AAMDB AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNGD ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABQTQ ABVGC ABXVV ABZBJ ACFRR ACGFO ACGFS ACPRK ACUFI ACUKT ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEHUL AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFZL AFIYH AFOFC AFXAL AGINJ AGKEF AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQDSO ATGXG ATTQO AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EE~ EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M49 MHKGH N9A NGC NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBH OCZFY ODMLO OHH OJQWA OJZSN OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y R44 RD5 RIG RNI ROL ROX RUSNO RW1 RXO RZF RZO SV3 TCURE TEORI TJX TMA TR2 VVN W8F WOQ X7H YAYTL YKOAZ YXANX ZGI ZKX ZY1 ~91 AAYXX AHGBF AJBYB CITATION ADJQC ADRIX AFXEN NPM OK1 RHF 7X8  | 
    
| ID | FETCH-LOGICAL-c347t-fb7d1986e01ea26c9072d1c3447fa59f7edd1fa155bda119f8cea607fea9c2f63 | 
    
| ISSN | 1462-0324 1462-0332  | 
    
| IngestDate | Wed Oct 01 14:34:40 EDT 2025 Wed Feb 19 02:25:46 EST 2025 Wed Oct 01 04:43:18 EDT 2025 Thu Apr 24 22:51:11 EDT 2025 Wed Apr 02 07:04:32 EDT 2025  | 
    
| IsPeerReviewed | true | 
    
| IsScholarly | true | 
    
| Issue | 6 | 
    
| Keywords | idiopathic inflammatory myopathy treatment plasma exchange therapy anti-SRP antibody  | 
    
| Language | English | 
    
| License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.  | 
    
| LinkModel | OpenURL | 
    
| MergedId | FETCHMERGED-LOGICAL-c347t-fb7d1986e01ea26c9072d1c3447fa59f7edd1fa155bda119f8cea607fea9c2f63 | 
    
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23  | 
    
| ORCID | 0000-0002-4825-5227 0000-0001-9587-1180 0000-0002-0358-8933  | 
    
| PMID | 34508561 | 
    
| PQID | 2571924837 | 
    
| PQPubID | 23479 | 
    
| PageCount | 6 | 
    
| ParticipantIDs | proquest_miscellaneous_2571924837 pubmed_primary_34508561 crossref_citationtrail_10_1093_rheumatology_keab629 crossref_primary_10_1093_rheumatology_keab629 oup_primary_10_1093_rheumatology_keab629  | 
    
| ProviderPackageCode | CITATION AAYXX  | 
    
| PublicationCentury | 2000 | 
    
| PublicationDate | 2022-05-30 | 
    
| PublicationDateYYYYMMDD | 2022-05-30 | 
    
| PublicationDate_xml | – month: 05 year: 2022 text: 2022-05-30 day: 30  | 
    
| PublicationDecade | 2020 | 
    
| PublicationPlace | England | 
    
| PublicationPlace_xml | – name: England | 
    
| PublicationTitle | Rheumatology (Oxford, England) | 
    
| PublicationTitleAlternate | Rheumatology (Oxford) | 
    
| PublicationYear | 2022 | 
    
| Publisher | Oxford University Press | 
    
| Publisher_xml | – name: Oxford University Press | 
    
| References | Pinal-Fernandez (2022060107564816500_keab629-B10) 2017; 76 Ning (2022060107564816500_keab629-B18) 2019; 6 Aggarwal (2022060107564816500_keab629-B20) 2015; 54 Abe (2022060107564816500_keab629-B17) 2020; 59 Bohan (2022060107564816500_keab629-B6) 1975; 292 Cozzi (2022060107564816500_keab629-B16) 2015; 53 Rothman (2022060107564816500_keab629-B9) 1990; 1 Watanabe (2022060107564816500_keab629-B11) 2016; 87 Kassardjian (2022060107564816500_keab629-B4) 2015; 72 Suzuki (2022060107564816500_keab629-B3) 2015; 10 Dimitri (2022060107564816500_keab629-B2) 2007; 35 Cherin (2022060107564816500_keab629-B15) 1995; 13 Herson (2022060107564816500_keab629-B14) 1989; 140 Aggarwal (2022060107564816500_keab629-B8) 2017; 76 Rider (2022060107564816500_keab629-B7) 2004; 50 Reeves (2022060107564816500_keab629-B1) 1986; 83 Shirakashi (2022060107564816500_keab629-B5) 2020; 59 Bergua (2022060107564816500_keab629-B19) 2019; 78 Miller (2022060107564816500_keab629-B12) 1992; 326 Dau (2022060107564816500_keab629-B13) 1981; 38  | 
    
| References_xml | – volume: 35 start-page: 389 year: 2007 ident: 2022060107564816500_keab629-B2 article-title: Myopathy associated with anti-signal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology publication-title: Muscle Nerve doi: 10.1002/mus.20693 – volume: 13 start-page: 270 year: 1995 ident: 2022060107564816500_keab629-B15 article-title: Plasma exchange in polymyositis and dermatomyositis: a multicenter study of 57 cases publication-title: Clin Exp Rheumatol – volume: 38 start-page: 544 year: 1981 ident: 2022060107564816500_keab629-B13 article-title: Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients publication-title: Arch Neurol doi: 10.1001/archneur.1981.00510090038003 – volume: 50 start-page: 2281 year: 2004 ident: 2022060107564816500_keab629-B7 article-title: International consensus on preliminary definitions of improvement in adult and juvenile myositis publication-title: Arthritis Rheum doi: 10.1002/art.20349 – volume: 59 start-page: 767 year: 2020 ident: 2022060107564816500_keab629-B17 article-title: Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy publication-title: Rheumatology doi: 10.1093/rheumatology/kez357 – volume: 6 start-page: 239 year: 2019 ident: 2022060107564816500_keab629-B18 article-title: Efficiency of therapeutic plasma-exchange in acute interstitial lung disease, associated with polymyositis/dermatomyositis resistant to glucocorticoids and immunosuppressive drugs: a retrospective study publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2019.00239 – volume: 1 start-page: 43 year: 1990 ident: 2022060107564816500_keab629-B9 article-title: No adjustments are needed for multiple comparisons publication-title: Epidemiology doi: 10.1097/00001648-199001000-00010 – volume: 140 start-page: 453 year: 1989 ident: 2022060107564816500_keab629-B14 article-title: Plasma exchange in dermatomyositis and polymyositis. Retrospective study of 38 cases of plasma exchange publication-title: Ann Med Interne – volume: 83 start-page: 9507 year: 1986 ident: 2022060107564816500_keab629-B1 article-title: Human autoantibodies reactive with the signal-recognition particle publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.83.24.9507 – volume: 53 start-page: 368 year: 2015 ident: 2022060107564816500_keab629-B16 article-title: Plasma-exchange as a “rescue therapy” for dermato/polymyositis in acute phase. Experience in three young patients publication-title: Transfus Apher Sci doi: 10.1016/j.transci.2015.07.005 – volume: 10 start-page: 61 year: 2015 ident: 2022060107564816500_keab629-B3 article-title: Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients publication-title: Orphanet J Rare Dis doi: 10.1186/s13023-015-0277-y – volume: 78 start-page: 131 year: 2019 ident: 2022060107564816500_keab629-B19 article-title: In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2018-213518 – volume: 59 start-page: 3284 year: 2020 ident: 2022060107564816500_keab629-B5 article-title: Efficacy of plasma exchange in anti-MDA5-positive dermatomyositis with interstitial lung disease under combined immunosuppressive treatment publication-title: Rheumatology doi: 10.1093/rheumatology/keaa123 – volume: 72 start-page: 996 year: 2015 ident: 2022060107564816500_keab629-B4 article-title: Clinical features and treatment outcomes of necrotizing autoimmune myopathy publication-title: JAMA Neurol doi: 10.1001/jamaneurol.2015.1207 – volume: 76 start-page: 681 year: 2017 ident: 2022060107564816500_keab629-B10 article-title: Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2016-210198 – volume: 292 start-page: 344 year: 1975 ident: 2022060107564816500_keab629-B6 article-title: Polymyositis and dermatomyositis (first of two parts) publication-title: N Engl J Med doi: 10.1056/NEJM197502132920706 – volume: 76 start-page: 792 year: 2017 ident: 2022060107564816500_keab629-B8 article-title: 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2017-211400 – volume: 326 start-page: 1380 year: 1992 ident: 2022060107564816500_keab629-B12 article-title: Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis publication-title: N Engl J Med doi: 10.1056/NEJM199205213262102 – volume: 54 start-page: 1194 year: 2015 ident: 2022060107564816500_keab629-B20 article-title: Anti-signal recognition particle autoantibody ELISA validation and clinical associations publication-title: Rheumatology doi: 10.1093/rheumatology/keu436 – volume: 87 start-page: 1038 year: 2016 ident: 2022060107564816500_keab629-B11 article-title: Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy publication-title: J Neurol Neurosurg Psychiatry doi: 10.1136/jnnp-2016-313166  | 
    
| SSID | ssj0005138 | 
    
| Score | 2.430274 | 
    
| Snippet | Abstract
Objectives
To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive... To explore the efficacy of plasma exchange (PE) therapy in refractory idiopathic inflammatory myopathy (IIM) patients with positive anti-signal recognition...  | 
    
| SourceID | proquest pubmed crossref oup  | 
    
| SourceType | Aggregation Database Index Database Enrichment Source Publisher  | 
    
| StartPage | 2625 | 
    
| Title | Plasma exchange therapy in refractory inflammatory myopathy with anti-signal recognition particle antibody: a case series | 
    
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34508561 https://www.proquest.com/docview/2571924837  | 
    
| Volume | 61 | 
    
| hasFullText | 1 | 
    
| inHoldings | 1 | 
    
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1462-0332 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005138 issn: 1462-0324 databaseCode: KQ8 dateStart: 19960101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1462-0332 dateEnd: 20241102 omitProxy: true ssIdentifier: ssj0005138 issn: 1462-0324 databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1462-0332 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005138 issn: 1462-0324 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research  | 
    
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFA7jCuLL4t3xRgQfhKG7TdNJp76JKIO44sMujE8lt7pFp5XZFnb8Z_47Ty7tpK7ori9lGpLTSc_XnFzO-Q5CL3JqkJGpSJYijtK5IvDNSeOZI5SOpWRUmw39o49seZK-X81Xk8nPwGupa8WB_PHHuJL_0SqUgV5NlOwVNDsIhQL4DfqFK2gYrpfS8SeY-q75TJ-78N2ZC6bauhiVcmNT6Zi7EtS-dsfp621jkhBv-6C2toqMC4el9_euRI1hW3UPsxVE42ih-EyCyZuZnnnHw57Y-1R3RrxlczL0pee9x7xPERJsNwwb1Eve7A6k7ND3uRtA9qHqbJ0G2utq54KgXdtVxU3Y2pdwywJWu-a0PQ5G2ZRBGXXB0wc6LKOjodnxtHsIjsZZ5sKlvc1OmBN_wR44rqxN8Brg9qvmgvmOjwi4fzOMg7uiO6inRSin8FKuoesJGBSbNWQVeBcRm0R96GkftZnTw1DKoZcymhWNIi0vLHjsxOf4Ftr3Kxb82iHiNpro-g66ceR9Mu6irUMh7lGIPQpxVeMdCnGIQtyjEBsU4gCFOEAh7lGIexS-whwbDGKHwXvo5N3b4zfLyCf0iCRNszYqRaZIvmA6JponTOZxligiDelkyed5mWmlSMlhiisUJyQvF1JzFmel5rlMSkbvo726qfVDhFkeQyVFMx7LlMSCz4nKOdWEaKoElVNE-xdaSM92b5KufCv-pswpioZW3x3byz_qvwRdXbLq816hBYzg5liO17rpzgowmmYXZEGzKXrgND1IpCksoGCJ8-iKf-wxurn78J6gvXbT6acwe27FM4vTXwlg098 | 
    
| linkProvider | Geneva Foundation for Medical Education and Research | 
    
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+exchange+therapy+in+refractory+inflammatory+myopathy+with+anti-signal+recognition+particle+antibody%3A+a+case+series&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Zhang%2C+Hao&rft.au=Sun%2C+Yue&rft.au=Liu%2C+Honglei&rft.au=Cheng%2C+Xiaobing&rft.date=2022-05-30&rft.issn=1462-0324&rft.eissn=1462-0332&rft.volume=61&rft.issue=6&rft.spage=2625&rft.epage=2630&rft_id=info:doi/10.1093%2Frheumatology%2Fkeab629&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_rheumatology_keab629 | 
    
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon | 
    
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon | 
    
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon |